0.3418
Lexicon Pharmaceuticals Inc stock is traded at $0.3418, with a volume of 47.60M.
It is down -51.17% in the last 24 hours and down -53.04% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
See More
Previous Close:
$0.6995
Open:
$0.3746
24h Volume:
47.60M
Relative Volume:
8.79
Market Cap:
$147.85M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-0.4273
EPS:
-0.8
Net Cash Flow:
$-162.37M
1W Performance:
-51.35%
1M Performance:
-53.04%
6M Performance:
-78.78%
1Y Performance:
-86.23%
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
LXRX
Lexicon Pharmaceuticals Inc
|
0.3423 | 147.85M | 1.21M | -177.12M | -162.37M | -0.80 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
490.02 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
688.15 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
634.08 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
242.19 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
BNTX
Biontech Se Adr
|
112.76 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-17-24 | Initiated | H.C. Wainwright | Buy |
Apr-30-24 | Initiated | Leerink Partners | Outperform |
Mar-07-23 | Initiated | Jefferies | Hold |
Aug-12-22 | Initiated | Piper Sandler | Overweight |
Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
Jul-29-19 | Downgrade | Stifel | Buy → Hold |
Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
Jul-31-18 | Reiterated | Stifel | Buy |
Feb-23-18 | Downgrade | Needham | Buy → Hold |
Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
Mar-01-17 | Reiterated | Wedbush | Outperform |
Oct-07-16 | Initiated | H.C. Wainwright | Buy |
Aug-05-16 | Reiterated | Wedbush | Outperform |
Aug-02-16 | Initiated | Citigroup | Buy |
Mar-02-16 | Reiterated | Wedbush | Outperform |
Nov-09-15 | Reiterated | Wedbush | Outperform |
Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
Lexicon Pharmaceuticals (LXRX) Stock Is Down: What's Going On? - Benzinga
Lexicon Says Pilavapadin Showed 'Meaningful' Pain Reduction But Results Miss Primary Endpoint - Marketscreener.com
Lexicon Pharmaceuticals stock tumbles after clinical study results - Investing.com India
Lexicon advances pilavapadin into Phase 3 for diabetic pain - Investing.com India
Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain - The Manila Times
Lexicon Pharma (LXRX) Announces Topline Results from Phase 2b PROGRESS Study - StreetInsider.com
Can Lexicon's Non-Opioid Pain Drug Break 20-Year Innovation Drought? Phase 2b Results Reveal Path Forward - StockTitan
Lexicon Pharma To Announce Topline Results From Phase 2b PROGRESS Study Today - Nasdaq
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain - The Manila Times
Lexicon Pharmaceuticals to Host Conference Call on Phase 2b Results for Pilavapadin in Diabetic Peripheral Neuropathic Pain - Nasdaq
Can Lexicon's Non-Opioid Drug Transform Diabetic Pain Treatment? Phase 2b Results Coming - StockTitan
Lexicon Pharmaceuticals, Inc. Announces Resignation of Praveen Tyle as Executive Vice President, Research and Development, Effective as of April 26, 2021 - Marketscreener.com
Lexicon to cut 50% of workforce to focus on sotagliflozin - MSN
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE) - Yahoo Finance
Revolutionary Diabetes Drug Cuts Heart Attack Risk by 32%Landmark Study Results - StockTitan
Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain - News & Insights
Merck: 4 No-Brainer Reasons to Buy This Dip - The Globe and Mail
Peripheral Neuropathic Pain Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Grünenthal and Averitas Pharma, Scilex Pharma, Apurano Pharma, Lexicon Pharma, Helixmith - Barchart
Peripheral Neuropathic Pain Market to Show Remarkable Growth - openPR
George Medicines appoints Amy Carroll as Senior Vice President of Medical Affairs - GlobeNewswire Inc.
Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns "Hold" Rating from Needham & Company LLC - MarketBeat
Lexicon Pharmaceuticals (NASDAQ:LXRX) Given "Buy" Rating at HC Wainwright - MarketBeat
HC Wainwright Reiterates "Buy" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
More Heart, Less Skin: US FDA’s 2025 Novel Approvals Should Reflect Pipeline Shifts - Citeline News & Insights
Lexicon Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista - MSN
9 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain - The Manila Times
Lexicon Pharma to Host Expert Panel on Groundbreaking Non-Opioid Pain Treatment LX9211 - StockTitan
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Lexicon Pharmaceuticals faces potential Nasdaq delisting - Investing.com India
Lexicon Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com Nigeria
Strong week for Lexicon Pharmaceuticals (NASDAQ:LXRX) shareholders doesn't alleviate pain of five-year loss - Simply Wall St
Here’s Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10 - Insider Monkey
Lexicon Pharmaceuticals, Inc. Appoints Scott M. Coiante as Senior Vice President - Marketscreener.com
Lexicon Pharmaceuticals, Inc. Announces CFO Changes - Marketscreener.com
Lexicon Pharmaceuticals, Inc. Appoints Scott Coiante as Senior Vice President - Marketscreener.com
Lexicon Appoints Scott Coiante as Chief Financial Officer - The Manila Times
Lexicon Pharmaceuticals Names Scott Coiante Finance Chief - MarketWatch
Lexicon Pharma (LXRX) Appoints Scott Coiante as CFO - StreetInsider.com
Lexicon Pharmaceuticals Names Veteran Pharma Executive Scott Coiante as New CFO - StockTitan
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX), ProShares Short VIX Short-Term Futures ETF (SVXY) & Alta Mesa Resources, Inc. f/k/a Silver Run Acquisition Cor - AccessWire
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Acquired by State Street Corp - Defense World
Private equity firms account for 47% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while institutions account for 33% - Yahoo Finance
Sotagliflozin Not Approved as Type 1 Diabetes Add-On - Medscape
Lexicon Pharmaceuticals (NASDAQ:LXRX) Receives “Hold” Rating from Needham & Company LLC - Defense World
Lexicon Zynquista vista narrows with diabetes CRL; gain due in pain? - BioWorld Online
Needham & Company LLC Reiterates Hold Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Analyst Expectations For Lexicon Pharmaceuticals's Future - Benzinga
XTX Topco Ltd Makes New Investment in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Defense World
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) - The Manila Times
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexicon Pharmaceuticals Inc Stock (LXRX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Swain Judith L | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
48,364 |
SOBECKI CHRISTOPHER J | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
167,055 |
LEFKOWITZ ROBERT J MD | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
48,364 |
DEBBANE RAYMOND | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
1,348,879 |
BARKER SAM L | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
87,649 |
Amouyal Philippe | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
248,364 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):